Skip to main content
. 2019 Feb 13;16(2):394–403. doi: 10.1007/s13311-018-00708-x

Fig. 1.

Fig. 1

Voxel-based analysis of changes from baseline in the cerebral metabolic rate of glucose consumption (CMRglc) for participants who completed the study (uncorrected p < 0.001). (A) CMRglc was preserved in the cilostazol group, whereas (B) CMRglc decreased in the parietal lobes and inferior frontal gyri (IFG) in the placebo group. (C) Between-group comparison of changes in CMRglc. CMRglc in the left IFG was higher in the cilostazol group than that in the placebo group